A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)

Wilson, Eleanor; Covert, Emily; Hoffmann, Jennifer; Comstock, Emily; Emmanuel, Benjamin; Tang, Lydia; Husson, Jennifer; Chua, Joel V; Price, Angie; Mathur, Poonam; Rosenthal, Elana; Kattakuzhy, Sarah; Masur, Henry; Kottilil, Shyam

doi:10.1016/j.jhep.2019.05.021

Cited by 22 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This regimen is recommended for patients in whom previous DAA treatment has failed, although only limited data exist regarding the use of these regimens in HIV/HCV coinfected patients. The RESOLVE study[ 21 ], which evaluated the treatment efficacy of this regimen in coinfected patients with previous DAA treatment failure, revealed SVR12 of 82%; however, the small sample size of only 18 patients means that further research involving a larger number of patients is needed. Headache, diarrhea and nausea were the most commonly reported adverse events.…”

Section: Hcv With Daa Treatment Experiencementioning

confidence: 99%

Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Laiwatthanapaisan¹,

Sirinawasatien²

2021

WJCC

View full text Add to dashboard Cite

Hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection is a major problem among HIV-infected patients, resulting in increased morbidity and mortality rates due to the acceleration of liver fibrosis progression by HIV, leading to liver cirrhosis and hepatocellular carcinoma. Although the efficacy of direct-acting antiviral therapy in patients with HIV/HCV coinfection and HCV monoinfection are similar in terms of sustained virologic response rate, there are some additional complications that arise in the treatment of patients with HIV/HCV coinfection, including drug-drug interactions and HCV reinfection due to the high risk behavior of these patients. This review will summarize the current management of HIV/HCV coinfection.

show abstract

Section: Hcv With Daa Treatment Experiencementioning

confidence: 99%

Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Laiwatthanapaisan¹,

Sirinawasatien²

2021

WJCC

View full text Add to dashboard Cite

show abstract

“…Even in those coinfected HIV-HCV patients who failed a previous combination of DAAs, the RESOLVE study demonstrated that 12 wk of SOF-VEL-VOX was safe and effective. The treatment response was not diminished by HIV coinfection[ 59 ].…”

Section: The Effective and Safe Cure For Hepatitis Cmentioning

confidence: 99%

Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination

Tijera¹,

Servín-Caamaño²,

Servín-Abad³

2021

WJG

View full text Add to dashboard Cite

Chronic viral hepatitis is a significant health problem throughout the world, which already represents high annual mortality. By 2040, chronic viral hepatitis due to virus B and virus C and their complications cirrhosis and hepatocellular carcinoma will be more deadly than malaria, vitellogenesis-inhibiting hormone, and tuberculosis altogether. In this review, we analyze the global impact of chronic viral hepatitis with a focus on the most vulnerable groups, the goals set by the World Health Organization for the year 2030, and the key points to achieve them, such as timely access to antiviral treatment of direct-acting antiviral, which represents the key to achieving hepatitis C virus elimination. Likewise, we review the strategies to prevent transmission and achieve control of hepatitis B virus. Finally, we address the impact that the coronavirus disease 2019 pandemic has had on implementing elimination strategies and the advantages of implementing telemedicine programs.

show abstract

“…In the real-life studies cited above, including limited representations of coinfected patients, HIV did not seem to have a major impact on SVR12, as HCV cure rates were similar to those of patients without coinfection. The Resolve Study, a multicenter open-label study carried out by Wilson et al, evaluated the tolerability, efficacy, and safety of SOF/VEL/VOX treatment in HCV patients with and without HIV coinfection [17]. Seventyseven patients were included, all with HCV genotype 1 (75% 1a and 25% 1b); 17 patients (22%) were HIV coinfected and 40% were cirrhotic.…”

Section: Sof/vel/vox Retreatment In Difficult-to-treat Populationsmentioning

confidence: 99%

Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAAtreated Patients with Chronic Hepatitis C?

2020

Journal of Cellular Immunology

View full text Add to dashboard Cite

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY)

Cited by 22 publications

References 14 publications

Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination

Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAAtreated Patients with Chronic Hepatitis C?

Contact Info

Product

Resources

About